FDA Approves Trodelvy, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 7, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Trodelvy® (sacituzumab...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news